Abstract

Large numbers of hormone-releasing cells, approximately 109 endocrine cells, are required to treat type I diabetes patients by cell transplantation. The SOX9-positive pancreatic epithelium proliferates extensively during the early stages of pancreatic development. SOX9-positive pancreatic epithelium is thought to be an expandable cell source of β cells for transplantation therapy. In this study, we attempted to expand pancreatic progenitors (PPs: PDX1+/SOX9+) derived from four human iPSC lines in three-dimensional (3D) culture using a chemically defined medium and examined the potential of the derived PPs to differentiate into β-like cells. PPs from four human iPSC lines were maintained and effectively proliferated in a chemically defined medium containing epidermal growth factor and R-spondin-1, CHIR99021, fibroblast growth factor-7, and SB431542. PPs derived from one iPSC line can be expanded by more than 104-fold in chemically defined medium containing two of the fives, epidermal growth factor and R-spondin-1. The expanded PPs were also stable following cryopreservation. After freezing and thawing, the PPs proliferated without a decrease in the rate. PPs obtained after 50 days of culture successfully differentiated into insulin-positive β-like cells, glucagon-positive α-like cells, and somatostatin-positive δ-like cells. The differentiation efficiency of expanded PPs was similar to that of PPs without expansion culture.

Highlights

  • Pluripotent stem cells (PSCs), such as embryonic stem cells and induced pluripotent stem cells, have been suggested as sources for cell replacement therapy for type I diabetes[1,2]

  • Proliferation of pancreatic progenitors (PPs) derived from hiPSC in chemically defined medium containing epidermal growth factor (EGF) and RSPO1

  • While addition of EGF alone promoted the proliferation of PDX1+/SRY-box 9 (SOX9)+ progenitors, some differentiated into PDX1+/NKX6.1+ endocrine progenitors (Supplementary Fig. 2)

Read more

Summary

Introduction

Pluripotent stem cells (PSCs), such as embryonic stem cells and induced pluripotent stem cells (iPSCs), have been suggested as sources for cell replacement therapy for type I diabetes[1,2]. During the early stages of pancreatic development, SRY-box 9 (SOX9)-positive pancreatic epithelium proliferates extensively and undergoes branching morphogenesis[9] More committed cells, such as neurogenin 3 (NEUROG3, NGN3)-positive endocrine progenitors, exhibit a limited proliferation capacity[10]. These results were obtained using mice and mouse cells, SOX9-positive PPs derived from human pluripotent stem cells may be useful as an expandable cell source of β-like cells for transplantation therapy. We attempted to expand PPs (PDX1+/SOX9+) derived from four human iPSC lines in three-dimensional (3D) culture using chemically defined medium, and examined their cryopreservation and potential to differentiate into β-like cells

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.